- Business Wire•2 days agoExelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Exelixis, Inc. today announced results from a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory genitourinary tumors.
- Accesswire•2 days agoEasier Regulatory Environment Could Send Biotech Industry Skyrocketing in 2017: Today's Reports on Neuralstem and Exelixis
NEW YORK, NY / ACCESSWIRE / February 17, 2017 / Biotech stocks have continued to outperform the broader markets in 2017 as an expectation of easier regulatory environment and growing speculation of mergers ...
EXEL : Summary for Exelixis, Inc. - Yahoo Finance
Exelixis, Inc. (EXEL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||23.20 x 600|
|Ask||23.55 x 1000|
|Day's Range||22.40 - 23.29|
|52 Week Range||3.55 - 23.29|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-35.14|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|